Prior reports indicate that patients with chronic lymphocytic leukemia (CLL) may be at increased risk of subsequent neoplasms. This study quantified the risk of second cancers among 16 367 patients with CLL in the population-based Surveillance, Epidemiology and End Results Program. Overall, the observed/expected ratio (O/E) was 1.20 (95% confidence interval [CI], 1.15-1.26). Second cancer risks for patients who received chemotherapy only as the first course of treatment (O/E = 1.21) were similar to risks for those who received no treatment initially (O/E = 1.19). Significant excesses were found for Kaposi sarcoma (O/E = 5.09), malignant melanoma (O/E = 3.18), and cancers of the larynx (O/E = 1.72) and the lung (O/E = 1.66). Increased risks were also found for brain cancer among men (O/E =1.91) and for cancers of the stomach (O/E = 1.76) and bladder (O/E = 1.52) among women. Additional investigations of cancers after CLL are needed to explore the role of immunologic impairment and/or other etiologic influences.

Chronic lymphocytic leukemia (CLL) is a malignancy of mature B lymphocytes of unknown etiology.1 Prior studies have reported that site-specific excesses of second cancer may exist among patients with CLL.2 3 Patterns of subsequent neoplasms in these individuals may provide insight into etiologic factors associated with both malignancies. In the present study, we describe the risk of second cancers among a large number of patients with CLL reported to the population-based cancer registries that comprise the Surveillance, Epidemiology and End Results (SEER) Program.

Patients and methods

Included in the present analysis are 16 367 patients with CLL registered in the SEER Program between 1973 and 1996. Data describing 9456 of these patients, diagnosed through 1988, were reported in a previous publication.3 Follow-up for this subgroup is now updated from 1989 to 1996. Person-years of observation began from 2 months after the date of CLL diagnosis to the date of last follow-up, death, diagnosis of a second cancer, or the end of the study (December 31, 1996), whichever occurred first. Expected numbers of cancers were estimated from the multiplication of the SEER incidence rates specific for 5-year age, sex, race, and 5-year calendar year intervals by the accumulated person-years at risk. Risk of second cancers was estimated as the ratio of observed to expected number of cases (O/E) with 95% confidence intervals (CI), assuming a Poisson distribution. Cancer sites were classified according to the World Health Organization'sInternational Classification of Diseases for Oncology, Second Edition.4 For our analysis, we compared the 2 largest treatment groups, ie, those who received chemotherapy only as initial therapy and those who did not receive treatment. Neither information on subsequent courses of therapy nor information regarding the specific chemotherapeutic agents with which patients were initially treated was available in the SEER Program. As a surrogate, the study period was divided into 1973-1989 and 1990-1996; the former represents an era before the widespread use of nucleoside analogs for CLL, whereas in the latter period the greater availability of those cytotoxic agents made it more likely that patients with CLL may have received them.5,6 Diagnoses of secondary lymphopoietic malignancies that may represent transformation of CLL7 were excluded from the analyses.

Overall, 16 367 patients with CLL, including 5-year survivors (7024) and 10-year survivors (2479), were evaluated for second cancer risk, accumulating a total of 84 667 person-years of follow-up (Table1). The mean age at diagnosis was 69.7 years, and the average follow-up was 5.2 years. Second cancers occurred in 1820 patients (O/E = 1.20; 95% CI, 1.15-1.26). Risks of subsequent neoplasms in the < 1 year, 1-4 year, 5-9 year, and ≥ 10 year intervals following CLL diagnosis were 1.25, 1.25, 1.14, and 1.16, respectively (P for trend = .14). Second cancer risks for patients who received chemotherapy only as the first course of treatment (O/E = 1.21) were similar to risks for those who received no treatment initially (O/E = 1.19). No significant difference in risk of all solid tumors combined was found for patients diagnosed with CLL between 1973-1989 (O/E = 1.19) and 1990-1996 (O/E = 1.29).

Table 1.

Observed numbers and observed/expected ratios of solid tumors among 16 367 of the 2-month survivors of chronic lymphocytic leukemia reported to the SEER Program between 1973 and 1996

All patients (n = 16 367)Men (n = 9517)Women (n = 6850)
ObsO/EObsO/EObsO/E
All solid tumors* 1820 1.20 1210 1.22 610 1.18 
Specific sites       
 All buccal 42 1.02 35 1.13 0.71 
 Esophagus 14 0.80 14 1.02 [E] = 3.8 
 Stomach 47 1.10 24 0.81 23 1.76 
 Colon 206 1.13 110 1.01 96 1.23 
 Rectum 72 1.09 40 0.93 32 1.38  
 Liver, bile duct, gall bladder 19 0.73 11 0.68 0.80 
 Pancreas 45 0.96 32 1.19 13 0.65 
 Larynx 31 1.72 27 1.68 1.98 
 Lung 421 1.66 318 1.68 103 1.62 
 Female breast 141 0.97 — — 141 0.97 
 Uterine cervix 0.56 — — 0.56 
 Uterine corpus 23 0.68 — — 23 0.69 
 Ovary 18 0.92 — — 18 0.92 
 Prostate 338 1.01 338 1.01 — — 
 Testis 2.44 2.44 — — 
 Bladder 91 0.98 64 0.85 27 1.52 
 Kidney, renal pelvis, ureter 42 1.16 29 1.12 13 1.24 
 Melanoma 90 3.18 62 3.14 28 3.28 
 Eye 2.26 2.10 2.56  
 Brain, central nervous system 221-153 1.49 18 1.91 0.76 
 Thyroid 0.60 0.98 0.28  
 Kaposi sarcoma1-155 5.09 2.06 19.13 
 Other1-154 134 1.44 77 1.45 57 1.44 
All patients (n = 16 367)Men (n = 9517)Women (n = 6850)
ObsO/EObsO/EObsO/E
All solid tumors* 1820 1.20 1210 1.22 610 1.18 
Specific sites       
 All buccal 42 1.02 35 1.13 0.71 
 Esophagus 14 0.80 14 1.02 [E] = 3.8 
 Stomach 47 1.10 24 0.81 23 1.76 
 Colon 206 1.13 110 1.01 96 1.23 
 Rectum 72 1.09 40 0.93 32 1.38  
 Liver, bile duct, gall bladder 19 0.73 11 0.68 0.80 
 Pancreas 45 0.96 32 1.19 13 0.65 
 Larynx 31 1.72 27 1.68 1.98 
 Lung 421 1.66 318 1.68 103 1.62 
 Female breast 141 0.97 — — 141 0.97 
 Uterine cervix 0.56 — — 0.56 
 Uterine corpus 23 0.68 — — 23 0.69 
 Ovary 18 0.92 — — 18 0.92 
 Prostate 338 1.01 338 1.01 — — 
 Testis 2.44 2.44 — — 
 Bladder 91 0.98 64 0.85 27 1.52 
 Kidney, renal pelvis, ureter 42 1.16 29 1.12 13 1.24 
 Melanoma 90 3.18 62 3.14 28 3.28 
 Eye 2.26 2.10 2.56  
 Brain, central nervous system 221-153 1.49 18 1.91 0.76 
 Thyroid 0.60 0.98 0.28  
 Kaposi sarcoma1-155 5.09 2.06 19.13 
 Other1-154 134 1.44 77 1.45 57 1.44 

Person-years of observation were 84 667 for all patients, 46 997 for men, and 37 670 for women.

SEER indicates Surveillance, Epidemiology, and End Results; Obs, observed; O/E, observed/expected; [E], expected number of cases.

*

Excludes nonmelanoma skin cancers and lymphohematopoietic malignancies.

P < .05.

Includes cancers of antrum (4), cardia (4), greater and lesser curvatures (2), pylorus (2), fundus (1), overlapping lesion (3), and not otherwise specified (7). Histologic types include adenocarcinoma (21), signet cell carcinoma (1), and carcinoid tumor (1).

F1-153

Includes glioblastoma (16), meningioma (3), astrocytoma (2), and glioma (1).

F1-155

Absolute excesses of Kaposi sarcoma per 100 000 patients with CLL per year were 15 and 3 for women and men respectively.

F1-154

Includes 80 cancers of ill-defined or unknown primary site.

Significantly increased risks were observed for Kaposi sarcoma (KS) (O/E = 5.09), malignant melanoma (O/E = 3.18), and cancers of the larynx (O/E = 1.72) and the lung (O/E = 1.66). Men with CLL, but not women, experienced significantly increased risks of brain cancer (O/E = 1.91). In addition, significant excesses of cancers of the stomach (O/E = 1.76) and bladder (O/E = 1.52) were restricted to women.

Prior studies of patients with CLL have documented increased risks of various forms of skin cancer, including malignant melanoma,2,8-11 probably resulting from the immune perturbations.12 Risk of malignant melanoma is elevated in patients with therapeutic immune suppression associated with organ transplantation, and this risk is further enhanced by increases in sunlight exposure.13 However, the apparent excess of skin cancers in CLL may be partly due to the increased medical surveillance of these patients.

Clinical features of patients with CLL with subsequent KS (6 women, 3 men) are presented in Table 2. To our knowledge, we are the first to report an increased risk of KS among patients with CLL. Two-fold to 7-fold increased risks of KS have been observed among patients with all types of lymphoid malignancies combined (Hodgkin disease, non-Hodgkin lymphoma, and all leukemia),14,15 but risk estimates for CLL were not provided separately. In one registry-based study that reported a 3-fold risk of sarcoma after CLL,16 KS-specific risks were not estimated.

Table 2.

Characteristics of 9 patients with chronic lymphocytic leukemia who subsequently developed Kaposi sarcoma reported to the SEER Program, 1973-1996

CaseAge*SexRaceCLL (mo/y)KS (mo/y)Latency between
CLL and KS (mo)
KS siteSurvival after
KS (mo)
Cause of death
78 White 2/1976 3/1983 85 R lower limb CLL 
80 White 9/1980 8/1981 11 Skin, NOS Myocardial infarction 
67 Black 9/1983 12/1989 75 Skin, NOS 28 CLL 
73 White 2/1978 9/1982 55 L upper limb CLL 
66 White 6/1980 12/1988 102 B lower limbs 17 CLL 
66 White 6/1986 10/1994 100 Skin, NOS 26 (Alive) 
91 White 11/1988 8/1989 Skin, NOS Myocardial infarction 
70 White 12/1988 11/1990 23 Skin, NOS 27 CLL 
85 White 3/1995 5/1995 B lower limb KS 
CaseAge*SexRaceCLL (mo/y)KS (mo/y)Latency between
CLL and KS (mo)
KS siteSurvival after
KS (mo)
Cause of death
78 White 2/1976 3/1983 85 R lower limb CLL 
80 White 9/1980 8/1981 11 Skin, NOS Myocardial infarction 
67 Black 9/1983 12/1989 75 Skin, NOS 28 CLL 
73 White 2/1978 9/1982 55 L upper limb CLL 
66 White 6/1980 12/1988 102 B lower limbs 17 CLL 
66 White 6/1986 10/1994 100 Skin, NOS 26 (Alive) 
91 White 11/1988 8/1989 Skin, NOS Myocardial infarction 
70 White 12/1988 11/1990 23 Skin, NOS 27 CLL 
85 White 3/1995 5/1995 B lower limb KS 

CLL indicates chronic lymphocytic leukemia; KS, Kaposi sarcoma; SEER, Surveillance, Epidemiology, and End Results; R, right; L, left; B, bilateral; NOS, not otherwise specified.

*

Age at CLL diagnosis.

The increased risk of brain cancer among men with CLL is consistent with our earlier study,3 although the basis for this association remains unclear. The majority of brain cancers were glioblastomas that, in contrast to lymphomas of the central nervous system, have not been linked to compromised immune function. The excess risk of bladder cancer that we observed among women may be related to chemotherapy, particularly cyclophosphamide,17 although we did not have access to treatment information beyond the initial regimen. The increased risk of stomach cancer among women may be explained by an immune-related predisposition to Helicobacter pylori infection, an important risk factor for gastric carcinoma.18 However, these associations were limited to one sex, and they may have resulted from multiple statistical comparisons. Although increased medical surveillance may be involved also, the excess risks extended throughout the period of observation. The elevated risk of lung and laryngeal cancers in both sexes suggests the role of cigarette smoking, which may contribute to the increase of bladder19 and gastric cancers.20 Data on tobacco smoking were not available in our study, but it seems plausible that the carcinogenic effects of smoking are heightened by radiotherapy, chemotherapy, and/or immune deficiency.21 22 

Our data indicate that the overall risk of developing a second cancer is modestly but significantly elevated, independent of initial treatment, in persons with CLL compared with those in the general population. In terms of absolute risk, an excess of 366 solid tumors, including approximately 9 KSs, might be observed among 100 000 patients with CLL during each year of follow-up. Although the role of shared etiologic factors remains unclear, the pattern of excess cancers in CLL survivors suggests an influence of immunodeficiency associated with CLL.23 Given the prolonged survival of patients with CLL, it is important for physicians to be alert to the occurrence of second cancers, particularly when new symptoms or physical findings arise. It would also seem prudent to urge patients with CLL to avoid exposures to carcinogens such as tobacco smoke and excessive sunlight. Further studies of second cancers in CLL should address the role of shared risk factors, immunologic impairment, and/or other determinants. Where feasible, molecular probes should be included to elucidate the mechanisms underlying the constellation of tumors associated with CLL.

We thank Shannon Merkle for computing support, Rochelle Curtis and Lynn Ries for helpful discussions with regard to the SEER Program, and Dr James J. Goedert for critical review of the manuscript.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Bannerji
R
Byrd
JC
Update on the biology of chronic lymphocytic leukemia.
Curr Opin Oncol.
12
2000
22
29
2
Greene
MH
Hoover
RN
Fraumeni
JF
Jr
Subsequent cancer in patients with chronic lymphocytic leukemia—a possible immunologic mechanism.
J Natl Cancer Inst.
61
1978
337
340
3
Travis
LB
Curtis
RE
Hankey
BF
Fraumeni
JF
Jr
Second cancers in patients with chronic lymphocytic leukemia.
J Natl Cancer Inst.
84
1992
1422
1427
4
World Health Organization
International Classification of Diseases for Oncology
2nd ed.
1990
1
144
World Health Organization
Geneva, Switzerland
5
Carson
DA
Piro
LD
Wasson
DB
et al
Activity of 2-chloro-2'-deoxyadenosine in chronic lymphocytic leukemia, hairy cell leukemia, and autoimmune hemolytic anemia.
Adv Exp Med Biol.
253A
1989
427
431
6
Cheson
BD
Recent advances in the treatment of B-cell chronic lymphocytic leukemia.
Oncology.
4
1990
71
84
7
Giles
FJ
O'Brien
SM
Keating
MJ
Chronic lymphocytic leukemia in (Richter's) transformation.
Semin Oncol.
25
1998
117
125
8
Berg
JW
The incidence of multiple primary cancers: I. Development of further cancer in patients with lymphomas, leukemias, and myelomas.
J Natl Cancer Inst.
38
1967
741
752
9
Manusow
D
Weinerman
BH
Subsequent neoplasia in chronic lymphocytic leukemia.
JAMA.
232
1975
267
269
10
Gunz
FM
Angus
HB
Leukemia and cancer in the same patient.
Cancer.
18
1985
145
152
11
Levi
F
Randimbison
L
Te
VC
La Vecchia
C
Non Hodgkin's lymphomas, chronic lymphocytic leukemias and skin cancers.
Br J Cancer.
74
1996
1847
1850
12
Bartik
MM
Welker
D
Kay
NE
Impairments in immune cell function in B cell chronic lymphocytic leukemia.
Semin Oncol.
25
1998
27
33
13
Hoover
R
Effects of drugs— immunosuppression.
Origins of Human Cancer. Book A. Incidence of Cancer in Humans.
Hiatt
HH
Watson
JD
Winsten
JA
1977
369
379
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY
14
Iscovich
J
Boffetta
P
Winkelmann
R
Brennan
P
Classic Kaposi's sarcoma as a second primary neoplasm.
Int J Cancer.
80
1999
178
182
15
Dictor
M
Attewell
R
Epidemiology of Kaposi's sarcoma in Sweden prior to the acquired immunodeficiency syndrome.
Int J Cancer.
42
1988
346
351
16
Mellemgaard
A
Geisler
CH
Storm
HH
Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia.
Eur J Haematol.
53
1994
218
222
17
Travis
LB
Curtis
RE
Glimelius
B
et al
Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.
J Natl Cancer Inst.
87
1995
524
530
18
International Agency for Research on Cancer
Infection with Helicobacter pylori.
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.
61. Schistosomes, Liver Flukes and Helicobacter pylori
1996
177
240
IARC
Lyon, France
19
Baron
JA
Rohan
TE
Tobacco.
Cancer Epidemiology and Prevention
2nd ed.
Schottenfeld
D
Fraumeni
JF
Jr
1996
269
289
Oxford University Press
New York, NY
20
Chow
WH
Swanson
CA
Lissowska
J
et al
Risk of stomach cancer in relation to consumption of cigarettes, alcohol, tea and coffee in Warsaw, Poland.
Int J Cancer.
81
1999
871
876
21
Van Leeuwen
FE
Klokman
WJ
Stovall
M
et al
Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.
J Natl Cancer Inst.
87
1995
1530
1537
22
Swerdlow
AJ
Schoemaker
MJ
Allerton
R
et al
Lung cancer after Hodgkin's disease: a nested case–control study of the relation to treatment.
J Clin Oncol.
19
2001
1610
1618
23
Linet
MS
Cartwright
RA
The leukemias.
Cancer Epidemiology and Prevention
2nd ed.
Schottenfeld
D
Fraumeni
JF
Jr
1996
841
892
Oxford University Press
New York, NY

Author notes

Michie Hisada, National Cancer Institute, 6120 Executive Blvd, EPS 8008, Rockville, MD 20852; e-mail: [email protected].

Sign in via your Institution